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Abstract
Background: Little is known about users of electronic cigarettes, or their opinions, satisfaction or how and why they 
use such products.
Methods: An internet survey of 81 ever-users of ecigarettes in 2009. Participants answered open-ended questions on 
use of, and opinions about, ecigarettes.
Results: Respondents (73 current and 8 former users) lived in France, Canada, Belgium or Switzerland. Most 
respondents (77%) were men; 63% were former smokers and 37% were current smokers. They had used e-cigarettes 
for 100 days (median) and drew 175 puffs per day (median). Participants used the ecigarette either to quit smoking (53 
comments), to reduce their cigarette consumption (14 comments), in order not to disturb other people with smoke (20 
comments), or in smoke-free places (21 comments). Positive effects reported with ecigarettes included their usefulness 
to quit smoking, and the benefits of abstinence from smoking (less coughing, improved breathing, better physical 
fitness). Respondents also enjoyed the flavour of ecigarettes and the sensation of inhalation. Side effects included 
dryness of the mouth and throat. Respondents complained about the frequent technical failures of ecigarettes and 
had some concerns about the possible toxicity of the devices and about their future legal status.
Conclusions: Ecigarettes were used mainly to quit smoking, and may be helpful for this purpose, but several 
respondents were concerned about potential toxicity. There are very few published studies on ecigarettes and research 
is urgently required, particularly on the efficacy and toxicity of these devices.
Background
In recent years several manufacturers, mainly in China,
have produced electronic cigarettes (ecigarettes) that are
distributed in western countries, often by small, newly
established companies [1-4]. Electronic cigarettes look
and feel like cigarettes, but do not burn tobacco. The sev-
eral existing brands vary but, in general, ecigarettes con-
tain a battery and an electronic device that produces a
warm vapour or 'mist'. The vapour usually contains nico-
tine and often - but not always - contains propylene glycol
[5]. The vapour is inhaled and, as the user exhales, some
visible vapour is released, but no tobacco smoke. Some
ecigarettes also contain a light-emitting diode in the tip
that glows when the user puffs, to resemble the burning
end of a cigarette. The nicotine content of the cartridge
varies, and the cartridges usually contain chemical addi-
tives and flavours (such as various brands of tobacco,
chocolate, coffee, mint or fruit). The cartridges can usu-
ally be refilled, and refill bottles are provided with the
device.
Electronic cigarettes are probably less harmful than
tobacco smoking, but they are almost certainly more dan-
gerous than medicinal nicotine inhalers [6,7]. However, to
our knowledge, there is no published data on the safety of
ecigarettes. Internationally, the legality of ecigarettes var-
ies; they cannot be sold in Australia, Brazil, Canada, Den-
mark or Switzerland, but their sale is authorized in other
countries (e.g. China, New Zealand) [5,8,9]. Analyses
conducted by the United States Food and Drug Adminis-
tration (FDA) showed that ecigarettes contain carcino-
gens, including nitrosamines, toxic chemicals such as
diethylene glycol, and tobacco-specific components sus-
pected of being harmful to humans (anabasine, myos-
mine, and beta-nicotyrine) [6]. The FDA also found that
ecigarette cartridges labelled as containing no nicotine
did in fact contain low levels of nicotine. Some manufac-
turers do not disclose the ingredients in their products.
Furthermore, ecigarettes are not manufactured according
to the high standards imposed on pharmaceutical compa-
nies. Consequently, the inhaled vapour may contain
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impurities that may be dangerous to consumers [6]. In
particular, the origin of the nicotine itself is uncertain, as
pesticide-grade nicotine rather than pharmacological-
grade nicotine may be used in ecigarettes.
Little is known about ecigarettes, as few research
reports have been published [10,11]. In addition to the
FDA report mentioned above, reports from New Zea-
land, funded by Ruyan (a Chinese manufacturer of eciga-
rettes) concluded that the mist from the Ruyan ecigarette
contains acetaldehyde and mercury [12,13]. A ran-
domised trial in 40 smokers found that the Ruyan eciga-
rette delivered nicotine to the blood more rapidly than
the nicotine inhaler, but less rapidly than cigarettes, and
that the effect of the ecigarette on craving was similar to
that of the nicotine inhaler, but less than that of cigarettes
[14]. A recent U.S. study found that 10 puffs of an eciga-
rette delivered little or no nicotine [15].
The mist from ecigarettes is inhaled into the lung [13].
Although the particle size is apparently too small to
e n s u r e  d e p o s i t i o n  i n  t h e  l u ng alveoli [12], we are not
aware of any study of lung absorption of ecigarette mist.
Because lung inhalation may enable nicotine to pass rap-
idly into the blood, and thus rapidly relieve craving and
tobacco withdrawal symptoms [14], ecigarettes have the
potential to be at least as effective as currently approved
nicotine replacement therapy (NRT) products, none of
which deliver nicotine to the lung. In addition, the simi-
larities in shape, actions and inhalation between eciga-
rettes and tobacco cigarettes could also help smokers
quit. However, as there are no data to support the manu-
facturers' claims that ecigarettes help smokers quit, the
World Health Organization asked the companies not to
make any therapeutic claims [7,16]. If they claimed that
ecigarettes help smokers quit, manufacturers would be
subject to the legislation and regulation that applies to
NRT products. In order to avoid this, some ecigarettes
are now marketed for enjoyment, or as devices that
enable smokers to "smoke" everywhere, including smoke-
free places [3,4]. Nonetheless, some distributors present
their products as an alternative to tobacco smoking, more
or less implicitly suggesting that ecigarettes can be used
to aid smoking cessation [1,2].
One may hypothesize that the positive effects of eciga-
rettes may include smoking cessation, smoking reduction
or relapse prevention. The ecigarette could also be used
as an aid during a preparation period before cessation,
similar to the pre-cessation treatment or "cut down to
quit" approach that is an approved indication for NRT
[17]. On the other hand, ecigarettes may be dangerous
because of the frequent and longterm lung inhalation of
diethylene glycol, nicotine and other toxic components,
and because of the sub-standard manufacturing process,
relative to pharmaceutical products [7]. Because of its
rapid nicotine delivery [14], the ecigarette also has the
potential to be addictive. In addition, the refill bottles
may be dangerous as they contain up to one gram of nico-
tine, whereas the fatal dose of nicotine is estimated to be
30 to 60 mg for adults and 10 mg for children [5]. The
ecigarette may also enable smokers to continue to 'smoke'
in smoke-free environments, thus delaying or preventing
cessation in people who might otherwise quit. Finally, the
fruit and chocolate flavours may appeal to young people,
and this raises the concern that ecigarettes may facilitate
initiation of nicotine dependence in young never-smok-
ers [5]. However, none of these hypotheses has yet been
tested.
Because of the huge burden of tobacco-related death
and disease, and because ecigarettes have potential to
help smokers quit, there is an urgent need for research
into these products. First, there is a need to know why
and how these products are used, and whether users are
satisfied with them. The aim of this study was to assess
usage patterns of ecigarettes, reasons for use, and users'
opinions of these products.
Methods
As ecigarettes are mainly sold online, the internet is a log-
ical way to reach users. We therefore posted a survey
form, in French, on the smoking cessation website StopT-
abac.ch over a 34 day period between September and
October 2009. This website receives approximately
120,000 visitors per month and is principally visited
either by smokers who intend to quit or by recent quitters
[18,19]. Links to the survey were posted on websites that
either provide information about ecigarettes
(ecigmag.com, forumecigarette.com) or sell them (econo-
clope.com, sedansa.be). After discussion with the head of
the ethics committee of the Geneva University Hospitals
(community medicine section, the committee to which
our Institute is submitted), the study was exempted from
approval.
Eligible participants were people who declared that
they had ever used an ecigarette and who provided the
brand name of the ecigarette that they had used most
often. Subjects who did not name a brand were excluded,
because this raised doubts about whether they had actu-
ally used an ecigarette. On the survey form, participants
indicated whether they had ever used ecigarettes or were
currently using them (subdivided into daily user, non-
daily user, former user, never used). They also provided
the total number of days that they had been using eciga-
rettes, the brand they used most often, the nicotine dose
per unit, the flavour and the cost per package (using
open-ended questions). In addition, subjects indicated
whether ecigarettes had helped them to quit smoking,
and current users indicated the number of puffs per day
on ecigarettes.Etter BMC Public Health 2010, 10:231
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In response to open-ended questions, participants
wrote where they bought their ecigarettes, the reasons
why they used them, what they considered to be the ben-
eficial and undesirable effects of ecigarettes, and the most
positive and negative points about the product. If they
had stopped using ecigarettes, they explained why. Partic-
ipants also listed which questions they had asked them-
selves about ecigarettes, and gave their opinion on the
information leaflets or documents inserted in the eciga-
rette packages. Finally, they wrote general comments on
the ecigarette.
Other questions also covered smoking status (daily,
non-daily, former smoker, never smoker). Smokers stated
the number of cigarettes they smoked per day, and for-
mer smokers stated when they had quit smoking. Partici-
pants were asked to supply their age, sex and country of
residence.
Medians rather than means were used for continuous
variables because medians are less sensitive to outliers,
which can excessively influence means in small sample
sizes.
Results
Answers were obtained from 214 people, but 123 of these
had never used ecigarettes and ten did not name the
brand of their ecigarette. These 133 subjects were
excluded. All subsequent analyses included only the 81
respondents who declared that they had ever used eciga-
rettes and who indicated the brand that they had used
most often. These 81 respondents included 72 daily users
of ecigarettes, one non-daily user and eight former users
(Table 1). They were relatively young (median age 37
years), and most (77%) were men. Respondents lived in
France (81%), Belgium (8%), Canada (6%) and Switzer-
land (5%). Most (63%) were former smokers who had quit
smoking relatively recently (median duration of absti-
nence: 100 days) (Table 1).
Use of the electronic cigarette
Most respondents had been using the ecigarette for
slightly longer than three months, and current users took
175 puffs per day (median) from their device (Table 1).
Sixteen different brands of ecigarettes were named, the
most frequent being Janty (n = 17), Joye (n = 17), Sedansa
(n = 14), Econoclope (n = 9), Liberty-cig (n = 8), Smoke51
and Edsylver (n = 2 each). All these brands of ecigarette
deliver nicotine, and the median dose of nicotine per unit
was 14 mg. The preferred flavour (open-ended field, 78
answers) was tobacco (n = 46, various flavours, e.g. "Turk-
ish blend", "K-mel"), followed by mint (n = 6), fruit (n = 5,
e.g. "apple"), vanilla (n = 4), coffee (n = 3) and tea (n = 2).
Twelve respondents used several of these flavours.
Most respondents (n = 74; 94% of 79 answers) had
bought their ecigarette on the internet, two had bought
their device in China, two at a tobacco retail shop and one
had bought it second hand. When asked whether the
ecigarette helped them quit smoking, most respondents
(79%) answered "a lot" (Table 1).
When asked why they chose to use ecigarettes (three
open-ended fields, 225 comments), the most frequent
answers were: that they used it to quit smoking; for their
health (as ecigarettes were perceived to be less toxic than
tobacco, e.g.: "it is better for health than tobacco");
because ecigarettes are less expensive than regular ciga-
rettes; because ecigarettes can be smoked everywhere,
including smoke-free places (e.g.: "I don't need to go out-
side to smoke anymore"); to avoid disturbing other people
with second-hand smoke; for the pleasure of smoking it
Table 1: Characteristics of ecigarette users, and usage 
patterns
Characteristic
Number of respondents 81
Age, median (range), years 37 (19-65)
Men (%) 77
Smoking status (%)
Former smokers 63
Daily smokers 23
Occasional (non-daily) 
smokers
13
Cigarettes per day, in 
smokers (median)
12
Days of abstinence, in former 
smokers, median (25th and 
75th percentiles)
100 (30, 210)
Use of electronic cigarettes
Days of use of the e-cigarette, 
median (25th and 75th 
percentiles)
100 (30, 210)
Number of puffs per day, 
median (25th and 75th 
percentiles)
175 (90, 275)
Number of puffs per day, 
range
10 to 600
Price per package, median, 
Euros (U.S. dollars)
40 (60)
Median dose of nicotine per 
unit, mg (25th and 75th 
percentiles)
14 (10, 16)
Does (did) the e-cigarette 
help you quit smoking? (%)
Yes, a lot 79
Yes, somewhat 16
No, not at all 5Etter BMC Public Health 2010, 10:231
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(e.g.: "to continue to inhale, which is something I like"),
and to reduce their cigarette consumption (Table 2).
The most frequently cited beneficial effects of eciga-
rettes (two open-ended fields, 134 comments) were: that
it improved breathing and respiration (e.g.: "I have less
breathlessness on exertion"); that it helps to quit smoking
(e.g.: "I have quit smoking without problems"); that
respondents coughed less, expectorated less and had
fewer sore throats; that it improved their health and
physical fitness; and that it did not cause unpleasant
odours or bad breath (Table 3). Interestingly, one respon-
dent suggested that the ecigarette device might be useful
to administer other medications to the bronchia or lung.
The two open-ended fields on the undesirable effects of
ecigarettes elicited 61 comments (only half the number of
comments received on the beneficial effects). The most
frequent responses were that ecigarettes caused dry
mouth and throat, vertigo, headache or nausea (Table 3).
T h e  m os t  f r eq u e n t l y  ci t ed  pos i t i v e  f ea t u r e s  o f  ec i g a -
rettes (three open-ended fields, 208 comments) were:
that respondents liked the taste and variety of flavours;
they appreciated the beneficial effects of the ecigarette on
their health, breathing and cough; the absence of unpleas-
ant odours or bad breath; they appreciated the pleasure of
inhalation, and harsh sensation in the throat; they liked
the act of using the ecigarette, which is similar to smok-
ing; the ecigarette is less toxic than tobacco smoke; it
facilitates smoking cessation; and that it can be used
everywhere (Table 4).
Table 2: Reasons for using e-cigarettes: open-ended 
comments from e-cigarette users
Number of comments
To quit smoking 53
For health, as e-cigarettes 
were perceived to be less 
toxic than tobacco
49
Less expensive than regular 
cigarettes
26
Can be smoked everywhere, 
including smoke-free places
21
To avoid disturbing other 
people, or producing 
environmental tobacco 
smoke or the smell of stale 
smoke
20
For the pleasure of smoking, 
including the pleasure of 
inhaling and smoking-
related actions
19
To reduce cigarette 
consumption
14
Curious to test a new product 10
Ecigarettes taste and smell 
good
8
Previously failed to quit with 
either nicotine patch or 
bupropion
3
To get nicotine 2
Total (from three open-ended 
fields)
225
Table 3: Beneficial and undesirable effects of e-cigarettes: 
open-ended comments from ecigarette users
Number of comments
Beneficial effects (total from 
two open-ended fields)
134
Improves breathing and 
respiration
31
Less cough, less 
expectoration, fewer sore 
throats
23
Helps to quit smoking 20
Improves health and physical 
fitness
17
Improves sense of taste and 
smell
11
Does not cause unpleasant 
odours or bad breath
10
Helps to reduce cigarette 
consumption
7
Sleeps better 4
Less craving for cigarettes 4
Cost 4
Pleasure of smoking the e-
cigarette
2
Useful device to administer 
other medications to the 
bronchia or lung
1
Undesirable effects (total from 
two open-ended fields)
61
Dry mouth and throat 16
Vertigo, headache or nausea 7
Bad taste 4
Weight gain 3
Technical problems 
(batteries)
3
Difficult to accurately control 
dose of nicotine
3
Cost 3
No undesirable effects 13
Miscellaneous comments 9Etter BMC Public Health 2010, 10:231
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When asked about the three most negative aspects of
ecigarettes (three fields, 154 comments), respondents
complained in particular about the poor quality of the
devices. They also reported that that ecigarettes were dif-
ficult or impractical to use (e.g. "it is difficult to refill the
liquid"), that the dosage was difficult to adjust (either too
high or too low), that the liquid can leak out during use,
and complained about the lack of information on the
composition of the vapour and any health risks associated
with ecigarettes (Table 4).
Respondents also stated which questions they had
asked themselves about ecigarettes (three fields, 112
comments). This section showed that users wondered
whether ecigarettes were safe, what the effects on health
were, and whether ecigarettes are toxic (59 comments,
including five that specifically mentioned propylene gly-
col). Respondents were also concerned that the e-ciga-
rette might be banned, and about its future legal status
(19 comments, e.g.: "let's hope it will not be prohibited").
They wanted to know about the composition of the liquid
in the cartridge (10 comments, e.g.: "What exactly is the
content of this liquid?", including four comments on the
quality of the liquids), why no serious studies on eciga-
rettes have been published (5 comments), why ecigarettes
are not sold in pharmacies (4 comments) and why the
devices are not produced in western countries (3 com-
ments).
When asked to comment on the documentation that
accompanied their ecigarette (one field, 70 comments),
most respondents answered that the inserts were good or
satisfactory (31 comments), seven responded that they
were only adequate, 15 responded that they contained
too little information, four reported that there was no
explanatory leaflet with their ecigarette, and two com-
plained that there was no explanation of the health effects
of ecigarettes. Three people responded that they used the
internet and online discussion forums to obtain more
information on ecigarettes (e.g.: "the insert was very brief,
but fortunately, there are specialized internet discussion
forums").
The section that asked participants to write general
comments on the ecigarette (one field) elicited 64 com-
ments. Twenty-one comments were very positive or
enthusiastic (e.g. "brilliant" (6 times), "miracle product",
"unbelievable", "very satisfied"), and 11 were positive but
more neutral (e.g.: "good", "I recommend it"). Respon-
dents also considered that the ecigarette helped them
quit smoking (14 comments), that it was more effective
than either nicotine patch or bupropion (5 comments),
and that it enabled them to reduce their cigarette con-
sumption (3 comments). Three people feared that the
ecigarette would soon be banned. Four commented that
ecigarettes need technical improvement, and six wrote
negative comments (e.g.: "not helpful to quit", "avoid it").
Table 4: The most positive and negative aspects of 
ecigarettes: open-ended comments from e-cigarette users
Number of comments
Positive points (total from 
three open-ended fields)
208
Taste and variety of flavours 38
Beneficial effects on health, 
breathing and cough
26
No unpleasant odours or bad 
breath
23
Inhalation, including harsh 
sensation in the throat and 
pleasure of inhaling
16
Less toxic than tobacco 
smoke
15
Facilitates smoking cessation 15
Can be used everywhere (the 
freedom)
15
The gestures or actions 
(similar to smoking)
13
Ease of use, design 10
Less expensive than 
cigarettes
9
No environmental tobacco 
smoke
8
Facilitates smoking 
reduction
5
No ash, dirt, or burned 
clothes
5
Can choose the dose of 
nicotine and number of puffs
5
Relieves craving for tobacco 3
Improves sense of smell and 
taste
2
Negative points (total from 
three open-ended fields)
154
Poor quality, lack of reliability 
and frequent failures
40
Batteries discharge too 
rapidly
27
Too expensive 14
Bad taste 14
Difficult or impractical to use; 
dosage is difficult to adjust
10
The liquid may leak during 
usage
10
Only sold on the internet 9Etter BMC Public Health 2010, 10:231
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Eight respondents had stopped using ecigarettes, and
were asked to indicate why (two fields, 15 comments).
Reasons included: it did not help me quit smoking (6
comments); it did not taste like cigarettes (3 comments);
poor quality or not reliable (3 comments); because of
concerns about risks and side-effects of ecigarettes (3
comments).
Interestingly, several respondents used a neologism
(vapoter, in French) to describe the action of smoking an
ecigarette; this term probably originated from "vapour"
and spread in online discussion forums. The correspond-
ing terms used on English-language forums (e.g. eciga-
rette-forum.com) are "vaping" and "vaper".
Discussion
Although, for legal reasons, ecigarettes are mainly mar-
keted to current smokers either for enjoyment or for use
in smoke-free places, our results suggest that most people
who buy these products are current and former smokers
who use ecigarettes to help quit smoking, just as they
would use NRT. Our survey also showed that ecigarettes
were liked by users, and were used quite intensively by
this sample; almost all respondents were daily ecigarette
users, and the number puffs per day (175) was substan-
tial. However, as ecigarettes deliver about one-tenth of
the nicotine per puff compared to cigarettes [12], this
intensive puffing pattern may result in less exposure to
nicotine than smoking. Interestingly, the median duration
of ecigarette use corresponded to the median duration of
abstinence in former smokers (100 days in both cases).
Respondents reported more positive than negative
effects with ecigarettes: many reported positive effects on
the respiratory system (breathing better, coughing less),
which were probably associated with stopping smoking
[20]. The fact that ecigarettes do not produce any
unpleasant odours or environmental tobacco smoke was
also appreciated. Most importantly, many respondents
reported that the ecigarette helped them quit smoking,
and several compared it favourably with either nicotine
patch or bupropion. These preliminary findings, together
with data showing that ecigarettes relieve craving and
withdrawal [14], suggest that the ecigarette may be an
effective aid to smoking cessation, and therefore merits
serious investigation for this purpose. Ideally, future trials
should compare the efficacy of ecigarettes versus NRT
(particularly the nicotine inhaler), bupropion or vareni-
cline. However, as ecigarettes are probably more toxic
than NRT products [6], the former should probably only
be recommended to smokers if they are substantially
more effective than current NRTs, and if the toxic con-
stituents of ecigarettes can be eliminated.
Interestingly, dry mouth and throat was a frequent
adverse effect of the ecigarette. It may be useful to investi-
gate why this occurs and how it might be minimised. It
would also be interesting to investigate why ecigarettes
appeal more to men than to women. Many respondents
complained of the poor quality of ecigarettes, their fre-
quent failures, the lack of durability of cartridges and bat-
teries, and that the liquid sometimes leaks from the
device during usage. Apparently competition between
manufacturers has not yet resulted in products of suffi-
cient technical quality.
Although users' comments were generally positive,
many were concerned about the safety and toxicity of
ecigarettes, and questioned why no study has yet investi-
gated these aspects. Several respondents were also con-
cerned about the future legal status of ecigarettes, and
that they may possibly be banned. Indeed, health authori-
ties in several countries have published warnings about,
or have prohibited the sale of, ecigarettes [5-8]. From a
public health perspective, however, the question is
whether - at a population level - the potential benefits of
the ecigarette outweigh its drawbacks. If ecigarettes are
more effective than current NRTs, but are withdrawn
from the market until approved as smoking cessation
aids, ecigarette users might revert to smoking tobacco,
which is more hazardous than ecigarettes. This could
have a significant, negative impact on public health,
because it can take several years to obtain legal approval
for a new drug delivery system.
On the other hand, ecigarettes are not currently manu-
factured to the same rigorous standards as pharmaceuti-
cal products; they currently contain toxic components
and are therefore almost certainly less safe than NRT
products [6]. The legal status of the e-cigarette is unclear
in many countries, and its regulation is complex; it is nei-
ther classed as a tobacco product, nor food, nor is it regis-
tered as a medicine. From the legal perspective, there is a
difficult balance between the need to protect consumers
No studies or information on 
the composition of the 
vapour and the health risks of 
the e-cigarette
8
Cartridges do not last long 
enough
6
Difficult to stop using the 
ecigarette without relapsing 
to smoking
4
Too big or too heavy 3
Too often asked by friends or 
colleagues to explain the 
device
2
Miscellaneous 7
Table 4: The most positive and negative aspects of 
ecigarettes: open-ended comments from e-cigarette users 
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and the possibility now being offered to smokers to use a
new, acceptable and potentially effective device to stop
smoking. Given the enormous burden of disease and
death caused by tobacco smoking, there is an urgent need
for research into the toxicity, efficacy and public health
impact of ecigarettes [10]. In addition, whether devices
that resemble ecigarettes could be used to deliver medi-
cations other than nicotine to the lung and bronchia also
warrants investigation. As the manufacturers and distrib-
utors of ecigarettes are relatively small companies that
may be unable to afford the research costs, or possess the
expertise or manpower to go through the regulatory
approval process, support from governments, public
health organizations or foundations may be needed to
produce evidence on these novel devices.
One limitation of our study is that it was conducted in a
self-selected sample of internet users. Whether this
method over-sampled satisfied users, long-term users or
heavy users of ecigarettes is unknown. Compared to pop-
ulation-based samples of smo k e r s  i n  E u r o p e  o r  t h e
United States, visitors to the Stop-Tabac.ch website are
more likely to have made a quit attempt in the previous
year, are more motivated to quit smoking, are slightly less
dependent on tobacco, and are more highly educated
[18,19]. Thus, although our results provide useful and
interesting preliminary information on ecigarette users,
our findings may not be generalizable and should be
interpreted with caution.
Conclusions
Our results suggest that ecigarettes are used mainly to
quit smoking, and may be useful for this purpose. How-
ever, users were concerned about the potential toxicity of
these devices. Very few studies have investigated eciga-
rettes and research is now urgently required, particularly
to establish the efficacy and toxicity of these devices.
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